Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Gloucester MA, Beverly MA, Peabody MA, Winchester MA,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05929768

Phase 3, Recruiting
Active & ResponsiveNew

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Seattle WA
Sponsor: University of Washington

Sex: All

Age: 18+

Code: NCT07721259

Phase 2, Recruiting
Active & ResponsiveNew

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

for
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Location: Los Angeles CA
Sponsor: Stephen Shiao

Sex: All

Age: 18+

Code: NCT07015853

Phase 2, Recruiting
Active & Responsive

Study of Screening Brain MRIs in Stage IV Breast Cancer

for
Triple Negative Breast Cancer, HER2-positive Breast Cancer,
Location: Clearwater FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05115474

Phase 2, Recruiting
Active & Responsive

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

for
Anatomic Stage I Breast Cancer AJCC v8,
Location: Upland CA, Irvine CA, Lancaster CA, Duarte CA,
Sponsor: City of Hope Medical Center

Sex: Female

Age: 18+

Code: NCT07741968

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

for
Breast Cancer Triple Negative, Breast Cancer Stage II,
Location: Atlanta GA
Sponsor: Emory University

Sex: Female

Age: 18+

Code: NCT05877859

Recruiting
Active & Responsive

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Nashville TN
Sponsor: Vandana Abramson

Sex: All

Age: 18+

Code: NCT07016399

Phase 2, Recruiting
Active & Responsive

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

for
Triple Negative Breast Cancer, HER2-negative Breast Cancer,
Location: Fairfax VA, Orlando FL, Huntersville NC, Sarasota FL,
Sponsor: Dren Bio

Sex: All

Age: 18+

Code: NCT06999187

Phase 1, Recruiting
Active & Responsive

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for
Triple Negative Breast Neoplasms
Location: Quebec, Chicoutimi, Mineola NY, New York NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06841354

Phase 3, Recruiting
Active & Responsive

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

for
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer,
Location: Dothan AL, Grand Rapids MI, Omaha NE, Houston TX
Sponsor: Radiopharm Theranostics, Ltd

Sex: All

Age: 18+

Code: NCT07189871

Phase 1, Phase 2, Recruiting
Active & Responsive

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

for
Triple Negative Breast Cancer
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT06845319

Phase 2, Recruiting
Active & Responsive

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

for
Triple Negative Breast Cancer
Location: Tampa FL, Clearwater FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05528133

Phase 2, Recruiting
Active & Responsive

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

for
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms,
Location: Boston MA, Norfolk VA, Detroit MI, Centerville OH,
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05386108

Phase 1, Phase 2, Recruiting
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase 1, Recruiting
Active & Responsive

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Genital Neoplasm, Female,
Location: Boston MA, Bethesda MD, Toronto, Celebration FL,
Sponsor: Marengo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05592626

Phase 1, Phase 2, Recruiting
Active & Responsive

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

for
Cancer, Breast Cancer, Lung Cancer, Colon Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT03702309

Recruiting
Active & Responsive

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Scarborough ME, Worcester MA, Hartford CT, Norwalk CT,
Sponsor: Massive Bio, Inc.

Sex: All

Age: 0+

Code: NCT03452774

Recruiting
Active & Responsive

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for
Cancer, Colorectal Cancer, Solid Tumor,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: Parabilis Medicines, Inc.

Sex: All

Age: 18+

Code: NCT05919264

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer,
Location: New Haven CT, Lake Success NY, New York NY, Fairfax VA,
Sponsor: Cogent Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07361562

Phase 1, Recruiting
Active & Responsive

Biennial CEM in Women With a Personal History of Breast Cancer

for
Breast Cancer, Breast Neoplasms, Breast Cancer Female,
Location: Monroeville PA, West Mifflin PA, Pittsburgh PA,
Sponsor: Wendie Berg

Sex: Female

Age: 30 - 70+

Code: NCT06105749

Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial